FDA Clarifies Approach to Product-Specific Guidance Meetings for ANDAs

The FDA has finalized advice for generic drug sponsors on seeking meetings with the agency to discuss the impact of a new or revised product-specific guidance (PSG) on their ANDA development programs.
Source: Drug Industry Daily